Wird geladen...
Combination of KRAS Gene Silencing and PI3K Inhibition for Ovarian Cancer Treatment
The phosphoinositide 3-kinase (PI3K) and RAS signaling pathways are frequently co-activated and altered during oncogenesis. Owing to their regulatory cross-talk, the early attempts of targeting only one pathway have mostly ended up promoting the development of drug resistance. Here, we propose using...
Gespeichert in:
| Veröffentlicht in: | J Control Release |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7056267/ https://ncbi.nlm.nih.gov/pubmed/31838203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2019.12.019 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|